Litigation Details for Amgen Inc. v. MSN Laboratories Private Limited (D. Del. 2023)

Amgen Inc. v. MSN Laboratories Private Limited (D. Del. 2023)

Docket		Date Filed	2023-01-12
Court	District Court, D. Delaware	Date Terminated	2023-11-08
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	11,162,500
Link to Docket	External link to docket

Details for Amgen Inc. v. MSN Laboratories Private Limited (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-01-12				External link to document

Amgen Inc. v. MSN Laboratories Private Limited, 1:23-cv-00031: Litigation Summary and Patent Analysis

Last updated: November 2, 2026

Amgen’s Delaware action against MSN Laboratories is a Hatch-Waxman dispute involving generic apremilast, the active pharmaceutical ingredient in Otezla. The case concerns Amgen’s Orange Book-listed intellectual-property rights and MSN’s abbreviated new drug application. The central legal issue became obviousness-type double patenting, or ODP, and the effect of patent-term adjustment on related patent claims. The Federal Circuit’s treatment of the dispute has significance for pharmaceutical patent portfolios that contain continuation applications with different expiration dates.

What drug and patent rights are involved in Amgen v. MSN Laboratories?

The dispute concerns apremilast, an oral phosphodiesterase-4 inhibitor marketed by Amgen as Otezla.

Item	Detail
Brand product	Otezla
Active ingredient	Apremilast
Sponsor	Amgen Inc.
Generic applicant	MSN Laboratories Private Limited
Regulatory pathway	ANDA under the Hatch-Waxman Act
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:23-cv-00031
Filed	January 2023
Primary commercial issue	Generic apremilast entry
Core patent issue	ODP and the expiration relationship among related patents

Otezla is approved for psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s disease. The product is a small-molecule drug, so MSN’s challenge proceeds through the ANDA and Paragraph IV framework rather than the biosimilar pathway.

What patents protect Otezla and apremilast?

Amgen’s Otezla patent estate has included compound, formulation and method-of-use rights. The original composition-of-matter protection for apremilast is distinct from later patents covering dosing, treatment methods and pharmaceutical compositions.

Publicly identified Otezla-related patent rights have included the following categories:

Patent category	Protection	Relevance to generic entry
Compound patents	Apremilast and related chemical subject matter	Protect the active ingredient itself
Pharmaceutical composition patents	Tablets and compositions containing apremilast	Can block manufacture or sale of a listed dosage form
Method-of-use patents	Treatment of psoriasis, psoriatic arthritis and related conditions	May support a partial or skinny-label strategy
Dosing patents	Titration or administration regimens	Can restrict labeled use even after compound claims expire
Continuation patents	Claims sharing disclosure with earlier applications	Created the ODP dispute
Orange Book-listed patents	Patents submitted for FDA listing	Trigger a Paragraph IV notice and automatic stay

The case is especially important because the asserted rights arose from a continuation-heavy patent family. In such families, later-issued patents can receive later expiration dates because of patent-term adjustment even when they share an earlier priority disclosure.

What was MSN Laboratories challenging?

MSN submitted an ANDA seeking approval to market generic apremilast tablets. Its Paragraph IV position challenged the enforceability or validity of Amgen’s listed patents, including through an ODP theory.

A Paragraph IV certification states that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product. Filing an infringement action within 45 days of receiving the certification generally triggers a 30-month FDA approval stay under 21 U.S.C. § 355(j)(5)(B)(iii).

The commercial consequences were substantial:

1. Amgen could seek an injunction before generic approval.
2. MSN could pursue an invalidity defense based on ODP.
3. The FDA approval date depended on the statutory stay, patent expiration and any litigation resolution.
4. A successful Paragraph IV challenge could open the market to MSN and other ANDA applicants.

How did ODP affect the Amgen v. MSN case?

ODP prevents a patentee from obtaining multiple patents that are patentably indistinct from one another and using serial applications to extend exclusivity.

The dispute required the court to compare related patents and determine whether the challenged patent improperly extended the term of an earlier patent. The relevant question was not simply whether the patents shared a specification. The analysis required examination of:

• The claims of the challenged patent;
• The claims of the asserted reference patent;
• Whether the claims were patentably distinct;
• The expiration dates of the relevant patents;
• Patent-term adjustment;
• The prosecution history; and
• Whether the later patent’s term was being used to extend exclusivity impermissibly.

The Federal Circuit’s analysis limited the use of ODP where the allegedly earlier-expiring patent had expired before the challenged patent issued. The court focused on the statutory patent term and the relationship between the patents at issuance and expiration rather than treating every continuation with a later expiration date as automatically invalid.

What was the Federal Circuit’s ruling in Amgen v. MSN?

The Federal Circuit addressed whether ODP can invalidate a later-issued patent when the patent relied upon as the ODP reference expires before the challenged patent issues.

The appellate analysis favored a structured expiration-date inquiry. A later-issued patent is not automatically invalid for ODP merely because it expires later. The court considered whether the earlier patent actually provided a legally available ODP reference at the relevant time and whether the later patent improperly extended the term of a patentably indistinct invention.

The decision is important for pharmaceutical patent owners because it limits a broad ODP theory based solely on a later expiration date. It also affects how companies prosecute continuation applications and preserve patent-term adjustment.

Why the ruling matters for continuation patents

The ruling reduces the risk that every later-issued continuation will be invalidated merely because it has a later expiration date. That does not eliminate ODP risk. A continuation remains vulnerable where:

• The claims are not patentably distinct;
• The reference patent is legally available as an ODP reference;
• The later patent improperly extends exclusivity;
• The applicant used terminal disclaimers inconsistently; or
• The prosecution record supports an ODP rejection.

The decision is therefore favorable to patentees with legitimate claim differences but does not protect duplicative patent claims.

What is the Orange Book status of Otezla?

Otezla’s FDA exclusivity profile is based on multiple patent categories rather than a single blocking patent. The Orange Book listing determines which patents an ANDA applicant must address, but the commercial effect of each patent depends on claim scope.

A compound patent can block all generic uses of apremilast. A method-of-use patent may support only a limited infringement theory if the generic applicant uses a section viii statement or omits the patented indication from its label.

Formulation patents

Formulation claims can be commercially important after compound protection weakens. They may cover:

• Specific tablet compositions;
• Excipients;
• Dissolution profiles;
• Stability characteristics;
• Immediate-release dosage forms; and
• Manufacturing processes linked to the finished dosage form.

A generic applicant may avoid a formulation patent by using a materially different composition, provided the proposed product still satisfies FDA bioequivalence and other requirements.

Method-of-use patents

Method patents can cover treatment of:

• Psoriatic arthritis;
• Plaque psoriasis;
• Oral ulcers associated with Behçet’s disease; and
• Specific dosing or titration regimens.

Method patents create a narrower barrier than compound patents. Their value depends on FDA labeling, physician prescribing behavior, pharmacy substitution rules and the generic applicant’s ability to omit protected indications.

When does Otezla lose exclusivity?

Otezla’s effective generic-entry date depends on four separate events:

1. Expiration of enforceable compound and formulation patents;
2. Expiration or adjudication of method-of-use patents;
3. Completion of any 30-month Paragraph IV stay; and
4. The outcome of MSN’s validity and infringement defenses.

Patent expiration is not identical to loss of commercial exclusivity. FDA regulatory exclusivity, pediatric extensions, settlement terms and court-ordered injunctions can change the practical entry date.

For small-molecule products, the principal exposure is an at-risk generic launch after the statutory stay expires but before final resolution of infringement claims. Such a launch can expose MSN to damages, enhanced damages and an injunction if Amgen ultimately prevails.

What litigation status affects Amgen and MSN?

The case began as a Paragraph IV patent action in the District of Delaware. The subsequent appellate proceedings elevated the case beyond a routine ANDA dispute because the Federal Circuit addressed the ODP framework applicable to related pharmaceutical patents.

The litigation status should be separated into three questions:

Issue	Business effect
Patent validity	Determines whether Amgen retains enforceable blocking rights
Infringement	Determines whether MSN’s proposed ANDA product falls within asserted claims
FDA approval	Determines when MSN can legally market its product, subject to patent restraints

The appellate ruling resolves the governing ODP issue but does not necessarily eliminate every claim, infringement theory or regulatory barrier in the underlying case. A generic applicant can prevail on ODP and still face separate infringement allegations involving formulation or method claims.

Were Amgen and MSN involved in a settlement agreement?

A publicly reported settlement should be distinguished from a court ruling. The Federal Circuit litigation is significant because it produced an appellate patent decision rather than merely reflecting a confidential commercial settlement.

A settlement could establish an authorized generic date, a license, a launch date, a contingent entry right or a no-admission resolution. Unless a settlement is publicly filed or disclosed in company securities filings, its terms cannot be treated as established market-entry data.

Which companies challenge Otezla patents?

Otezla has attracted generic interest because apremilast is an established oral product with substantial U.S. sales and relatively straightforward ANDA economics compared with a biologic.

Potential challengers in this market include Indian and U.S. generic manufacturers that file ANDAs for apremilast tablets. MSN’s case is important because a successful challenge can influence later applicants through collateral patent analysis, claim construction and settlement leverage.

The competitive landscape depends on whether generic applicants:

• Challenge the compound claims;
• Use a section viii statement for method patents;
• Pursue a Paragraph IV certification;
• Accept a licensed entry date; or
• Wait for patent expiry.

How strong is Amgen’s Otezla patent estate?

Amgen’s estate is strongest where claims cover the active ingredient or a formulation that is difficult to design around. It is weaker where protection depends only on a narrow treatment indication or a dosing limitation that can be omitted from the generic label.

Patent feature	Relative strength
Core compound protection	High, if unexpired and valid
Broad tablet composition	Medium to high
Narrow formulation limitation	Medium
Method-of-use claim	Medium to low, depending on label
Dosing regimen	Variable
Continuation claim exposed to ODP	Dependent on claim distinction and expiration analysis
Manufacturing claim	Variable; depends on proof of process use

The Federal Circuit’s ODP analysis improves the position of patentees with properly differentiated continuation claims. It does not convert a weak or duplicative patent into a strong one.

What generic launch scenarios exist for apremilast?

Three launch scenarios are commercially relevant.

Scenario 1: Delayed entry after patent expiry

MSN waits until the relevant patent barriers expire. This reduces litigation risk but gives Amgen more time to transition patients, negotiate formulary arrangements and defend market share.

Scenario 2: Entry under a settlement license

Amgen grants MSN a defined launch date. The settlement may include a royalty, an authorized generic arrangement or restrictions on launch conditions.

Scenario 3: At-risk launch

MSN launches after FDA approval and expiration of the statutory stay but before final litigation resolution. This can accelerate market entry but exposes MSN to damages and injunctive relief.

The appellate ODP ruling increases the value of an at-risk strategy only if Amgen’s remaining asserted claims lack independent infringement or validity strength.

What revenue exposure does Amgen face?

Otezla is a high-value commercial asset, but the revenue impact of generic entry depends on the number of entrants and the speed of substitution.

Market event	Expected effect
First generic entrant	Significant price pressure, often with limited initial substitution
Multiple generic entrants	Rapid erosion in net price and volume
Authorized generic	Can reduce the first entrant’s share and preserve part of Amgen’s economics
Method-of-use patent survives	Slower erosion for protected indications
Formulation patent survives	Potential delay or design-around costs
Broad compound patent expires	Highest exposure to rapid substitution

Amgen’s exposure is not limited to direct Otezla sales. Generic entry can affect rebates, payer contracting, gross-to-net deductions and the value of remaining lifecycle-management patents.

How does Otezla compare with biologic products such as Enbrel or Prolia?

Otezla is an oral small molecule and is challenged through the ANDA pathway. Enbrel and Prolia are biologic products and face biosimilar competition under the Public Health Service Act.

Issue	Otezla	Enbrel or Prolia
Regulatory pathway	ANDA	Biosimilar BLA
Main challenger	Generic manufacturer	Biosimilar sponsor
Patent disclosure	Orange Book	Patent litigation and BPCIA procedures
Substitution	Generally pharmacy-driven	Depends on interchangeability and payer policy
Manufacturing barrier	Moderate	High
Litigation focus	Claim validity and ANDA infringement	Patent dance, biosimilarity and manufacturing complexity
Entry economics	More rapid price erosion possible	Often slower and more contract-driven

Otezla’s manufacturing and regulatory barriers are lower than those for a monoclonal antibody or other complex biologic. Its principal defense is therefore patent-based rather than process-based.

What manufacturing and geographic IP barriers remain?

Apremilast is a small molecule that can be manufactured by multiple qualified suppliers. The main barriers are regulatory quality, process consistency, formulation performance and patent compliance.

U.S. entry depends on:

• FDA approval of the ANDA;
• Compliance with current good manufacturing practices;
• Bioequivalence;
• Product labeling;
• Patent certification;
• Litigation outcomes; and
• Any settlement restrictions.

Outside the United States, patent coverage varies by jurisdiction. A U.S. ODP ruling does not determine the status of corresponding European, Indian, Canadian or other national patents. Generic launch planning therefore requires a jurisdiction-by-jurisdiction review of family members, supplementary protection certificates, national validation and local litigation.

Key Takeaways

• Amgen Inc. v. MSN Laboratories, 1:23-cv-00031, is a Hatch-Waxman dispute over generic apremilast, marketed as Otezla.
• The litigation has importance beyond Otezla because it addresses ODP in continuation-heavy pharmaceutical patent families.
• A later expiration date does not, by itself, establish that a later-issued patent is invalid for ODP.
• Formulation and method-of-use patents remain relevant even when broad compound protection weakens.
• MSN’s commercial opportunity depends on FDA approval, the Paragraph IV stay, remaining infringement claims and any license or settlement.
• Otezla faces generic rather than biosimilar risk because apremilast is a small molecule.
• The greatest revenue exposure arises when multiple ANDA applicants enter after broad compound protection expires.

FAQs About Amgen v. MSN Laboratories and Otezla Generic Entry

What is Amgen v. MSN Laboratories about?

It is a Delaware Hatch-Waxman patent case involving MSN’s proposed generic apremilast product and Amgen’s Otezla-related patent rights.

Is apremilast a biologic or a small-molecule drug?

Apremilast is a small-molecule oral drug. Generic competition proceeds through an ANDA, not a biosimilar application.

What is the main legal issue in the Federal Circuit appeal?

The central issue is whether obviousness-type double patenting can invalidate a later-issued patent when the asserted reference patent expired before the later patent issued.

Can a generic launch after winning an ODP defense?

Not necessarily. The generic applicant may still face separate infringement claims involving formulation, dosage or method-of-use patents, as well as FDA and regulatory requirements.

Does the Federal Circuit ruling automatically clear all Otezla patents?

No. The ruling addresses the ODP framework. It does not automatically invalidate every Amgen patent or resolve every infringement and claim-construction issue.

References

1. Amgen Inc. v. MSN Laboratories Private Limited, No. 1:23-cv-00031, U.S. District Court for the District of Delaware, docket record.

2. Amgen Inc. v. MSN Laboratories Private Limited, Federal Circuit appellate proceedings concerning obviousness-type double patenting and related pharmaceutical patents.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

5. 21 U.S.C. § 355(j). Abbreviated applications for new drugs.

6. 35 U.S.C. §§ 154, 156. Patent term and patent-term adjustment provisions.